Literature DB >> 25613107

Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population.

Lorcan McGarvey1, Amanda J Lee2, June Roberts3, Kevin Gruffydd-Jones4, Eddie McKnight5, John Haughney6.   

Abstract

BACKGROUND: The 'frequent exacerbator' is recognised as an important phenotype in COPD. Current understanding about this phenotype comes from prospective longitudinal clinical trials in secondary/tertiary care with little information reported in primary care populations. AIMS: To characterize the frequent-exacerbator phenotype and identify associated risk factors in a large UK primary care COPD population.
METHODS: Using a large database of primary care patients from 80 UK general practices, patients were categorised using GOLD 2014 criteria into high and low risk groups based on exacerbation history. A multivariate logistic regression model was used to investigate covariates associated with the frequent-exacerbator phenotype and risk of experiencing a severe exacerbation (leading to hospitalisation).
RESULTS: Of the total study population (n = 9219), 2612 (28%) fulfilled the criteria for high risk frequent-exacerbators. Independent risk factors (adjusted odds ratio [95% CI]) for ≥2 exacerbations were: most severely impaired modified Medical Research Council (mMRC) dyspnoea score (mMRC grade 4: 4.37 [2.64-7.23]), lower FEV1 percent predicted (FEV1 <30%: 2.42 [1.61-3.65]), co-morbid cardiovascular disease (1.42 [1.19-1.68]), depression (1.56 [1.22-1.99]) or osteoporosis (1.54 [1.19-2.01]), and female gender (1.20 [1.01-1.43]). Older patients (≥75 years), those with most severe lung impairment (FEV1 <30%), those with highest mMRC score and those with co-morbid osteoporosis were identified as most at risk of experiencing exacerbations requiring hospitalisation.
CONCLUSIONS: Although COPD exacerbations occur across all grades of disease severity, female patients with high dyspnoea scores, more severely impaired lung function and co-morbidities are at greatest risk. Elderly patients, with severely impaired lung function, high mMRC scores and osteoporosis are associated with experience of severe exacerbations requiring hospitalisation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Frequent exacerbator phenotype; Primary care

Mesh:

Year:  2014        PMID: 25613107     DOI: 10.1016/j.rmed.2014.12.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  24 in total

1.  Chronic bronchitis is associated with severe exacerbation and prolonged recovery period in Chinese patients with COPD: a multicenter cross-sectional study.

Authors:  Ying Liang; Yahong Chen; Rui Wu; Ming Lu; Wanzhen Yao; Jian Kang; Baiqiang Cai; Xin Zhou; Zheng Liu; Ping Chen; Dejun Sun; Jingping Zheng; Guoyang Wang; Yulin Feng; Yongjian Xu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Impact of mild exacerbation on COPD symptoms in a Japanese cohort.

Authors:  Minako Sato; Shotaro Chubachi; Mamoru Sasaki; Mizuha Haraguchi; Naofumi Kameyama; Akihiro Tsutsumi; Saeko Takahashi; Hidetoshi Nakamura; Koichiro Asano; Tomoko Betsuyaku
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-09

3.  "Frequent exacerbator" is a phenotype of poor prognosis in Japanese patients with chronic obstructive pulmonary disease.

Authors:  Ryusuke Tomioka; Tomotaka Kawayama; Masashi Suetomo; Takashi Kinoshita; Yoshihisa Tokunaga; Haruki Imaoka; Kazuko Matsunaga; Masaki Okamoto; Tomoaki Hoshino
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-03

Review 4.  A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.

Authors:  Anthony D'Urzo; James F Donohue; Peter Kardos; Marc Miravitlles; David Price
Journal:  Expert Opin Pharmacother       Date:  2015       Impact factor: 3.889

5.  Association between respiratory impedance measured by forced oscillation technique and exacerbations in patients with COPD.

Authors:  Hitomi Yamagami; Akihiko Tanaka; Yasunari Kishino; Hatsuko Mikuni; Tomoko Kawahara; Shin Ohta; Mayumi Yamamoto; Shintaro Suzuki; Tsukasa Ohnishi; Hironori Sagara
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-22

6.  Phenotype and management of chronic obstructive pulmonary disease patients in general population in China: a nationally cross-sectional study.

Authors:  Heling Bao; Guohua Jia; Shu Cong; Wanlu Sun; Jing Fan; Ning Wang; Yajing Feng; Baohua Wang; Jeffrey L Curtis; Linhong Wang; Liwen Fang; Yahong Chen
Journal:  NPJ Prim Care Respir Med       Date:  2021-06-01       Impact factor: 2.871

7.  Prevalence, risk factors, and health-related quality of life of osteoporosis in patients with COPD at a community hospital in Taiwan.

Authors:  Chun-Wei Lin; Yih-Yuan Chen; Yi-Jen Chen; Chi-Yen Liang; Ming-Shian Lin; Wei Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-29

Review 8.  Diagnosing COPD: advances in training and practice - a systematic review.

Authors:  Vladimir Koblizek; Barbora Novotna; Zuzana Zbozinkova; Karel Hejduk
Journal:  Adv Med Educ Pract       Date:  2016-04-04

9.  Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL Study.

Authors:  Eliana Ferroni; Valeria Belleudi; Silvia Cascini; Mirko Di Martino; Ursula Kirchmayer; Riccardo Pistelli; Elisabetta Patorno; Giulio Formoso; Danilo Fusco; Carlo A Perucci; Marina Davoli; Nera Agabiti
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

10.  Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Authors:  Martine Hoogendoorn; Talitha L Feenstra; Melinde Boland; Andrew H Briggs; Sixten Borg; Sven-Arne Jansson; Nancy A Risebrough; Julia F Slejko; Maureen Pmh Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.